secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-02-26T23:59:59+00:00
Accession:  0001651308-24-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows
--------------------------------------------------------------------------------

- Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).
- BRUKINSA global sales $413M in Q4 (+135% YoY) and $1.3B full year (+129%); U.S. revenue $313M in Q4.
- GAAP operating loss $383.8M in Q4, down 18% YoY; adjusted operating loss $267.2M, down 28%.
- FDA approved BRUKINSA label update for PFS superiority in CLL; EU approved for R/R follicular lymphoma.
- Advanced pipeline: sonrotoclax Phase 3 in CLL started; BTK CDAC BGB-16673 early data; TEVIMBRA CHMP positive opinion for NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/0001651308-24-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000011/bgne-20240226.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer